Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, announced that it is developing a new tablet formulation to add to its ZEGERID® family of branded prescription pharmaceutical products. The new formulation is a swallowable tablet that combines immediate-release omeprazole, a proton pump inhibitor (PPI), with a mix of buffers. Santarus plans to undertake clinical and stability studies with the tablet in preparation for the submission of a New Drug Application to the U.S.

CNS Response, Inc. (OTC Bulletin Board: CNSO) reported the results of a study presented at the American Psychiatric Association (APA) 161st Annual Meeting by Dr. James Greenblatt, M.D., Chief Medical Officer, Walden Behavioral Care Inpatient Psychiatry and Eating Disorder Programs.

Gastroesophageal reflux disease (GERD) is described as the chronic symptoms and/or tissue damage caused by the reflux of abnormal gastric contents to the esophagus. GERD is a common disease, with associated typical symptoms of heartburn and regurgitation. An article published in the World Journal of Gastroenterology evaluated the clinical and endoscopic features in Chinese patients with reflux esophagitis. This study was conducted by Dr.

TAP Pharmaceutical Products Inc. have reported results from three pivotal Phase 3 studies evaluating investigational new drug TAK-390MR, the first proton pump inhibitor (PPI) with an innovative dual delayed release technology, in healing patients with erosive esophagitis (EE) and in maintenance of healed EE. The data were presented at the Digestive Disease Week (DDW) annual meeting in San Diego.

Despite the growing availability of prescription and over-the-counter medications for gastroesophageal reflux disease (GERD), surgical treatment remains a viable alternative for patients whose symptoms persist. In the May 2008 Archives of Surgery, surgeons from Massachusetts General Hospital (MGH) report their survey of almost 200 patients who had laparoscopic antireflux surgery at the MGH over a 10-year period.

Title: Sorafenib Shows Promise for Heart-Lung Disease
Category: Health News
Created: 5/21/2008 2:00:00 AM
Last Editorial Review: 5/21/2008

Interim results from a nationwide clinical trial led by a University of North Carolina at Chapel Hill researcher suggest that radiofrequency ablation is an effective treatment for dysplasia in people with Barrett's esophagus, a condition that can lead to deadly gastrointestinal cancer. "The interim results show there is a substantial difference between treatment with radiofrequency ablation and a placebo or 'sham' treatment," said Dr.

A new, noninvasive gastroplasty device to treat two separate disorders gastroesophageal-reflux disease (GERD) and morbid obesity was reported by its inventor, Charles J. Filipi, M.D., professor of surgery at Creighton University School of Medicine. Filipi spoke about the device, which could be available for human trials later this year, on Monday, May 19, at the 49th annual Digestive Disease Week in San Diego, Calif.

As France's parliament considers a landmark bill that would outlaw media images glamorizing the extremely thin, psychology researchers are reporting some of the most definitive findings yet on how these images affect women. In the May issue of Psychological Bulletin, University of Wisconsin-Madison postdoctoral researcher Shelly Grabe and psychology professor Janet Hyde describe a sweeping analysis of 77 previous studies involving more than 15,000 subjects.

State Senators John Cullerton (D-6th District) and Heather Steans (D-7th District) will present a bill to the Illinois State Legislature Insurance Committee on May 8th that could have life or death consequences for the citizens of Illinois. Introduced by Rep. Fred Crespo (D-44th District), HB 1432 will strengthen the Illinois mental health insurance parity law by providing fair and equal insurance coverage for those suffering from anorexia nervosa and bulimia.